Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer’s disease

For amyloid positron emission tomography tracers, the simplified reference tissue model derived ratio of influx rate in target relative to reference region (R1) has been shown to serve as a marker of brain perfusion, and, due to the strong coupling between perfusion and metabolism, as a proxy for glucose metabolism. In the present study, 11 prodromal Alzheimer’s disease and nine Alzheimer’s disease dementia patients underwent [18F]THK5317, carbon-11 Pittsburgh Compound-B ([11C]PIB), and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography to assess the possible use of early-phase [18F]THK5317 and R1 as proxies for brain perfusion, and thus, for glucose metabolism. Discriminative performance (prodromal vs Alzheimer's disease dementia) of [18F]THK5317 (early-phase SUVr and R1) was compared with that of [11C]PIB (early-phase SUVr and R1) and [18F]FDG. Strong positive correlations were found between [18F]THK5317 (early-phase, R1) and [18F]FDG, particularly in frontal and temporoparietal regions. Differences in correlations between early-phase and R1 ([18F]THK5317 and [11C]PIB) and [18F]FDG, were not statistically significant, nor were differences in area under the curve values in the discriminative analysis. Our findings suggest that early-phase [18F]THK5317 and R1 provide information on brain perfusion, closely related to glucose metabolism. As such, a single positron emission tomography study with [18F]THK5317 may provide information about both tau pathology and brain perfusion in Alzheimer’s disease, with potential clinical applications.

[1]  Gunnar Antoni,et al.  Tracer Kinetic Analysis of (S)-18F-THK5117 as a PET Tracer for Assessing Tau Pathology , 2016, The Journal of Nuclear Medicine.

[2]  T. Yen,et al.  Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  N. Foster,et al.  Preserved Pontine Glucose Metabolism in Alzheimer Disease: A Reference Region for Functional Brain Image (PET) Analysis , 1995, Journal of computer assisted tomography.

[4]  Alexander Hammers,et al.  Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe , 2003, Human brain mapping.

[5]  Julie S. Snowden,et al.  Choice of reference region in the quantification of single-photon emission tomography in primary degenerative dementia , 1994, European Journal of Nuclear Medicine.

[6]  A. Gjedde,et al.  Blood-brain transfer of Pittsburgh compound B in humans , 2013, Front. Aging Neurosci..

[7]  Christopher C Rowe,et al.  Tau imaging: early progress and future directions , 2015, The Lancet Neurology.

[8]  M. Hüll,et al.  Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and 11C-Labeled Pittsburgh Compound B , 2011, The Journal of Nuclear Medicine.

[9]  Mike P. Wattjes,et al.  Cerebral perfusion and glucose metabolism in Alzheimer’s disease and frontotemporal dementia: two sides of the same coin? , 2015, European Radiology.

[10]  A. Gjedde,et al.  Washout allometric reference method (WARM) for parametric analysis of [11C]PIB in human brains , 2013, Front. Aging Neurosci..

[11]  J. Detre,et al.  Arterial spin labeling blood flow MRI: its role in the early characterization of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[12]  Gunnar Antoni,et al.  Unidirectional Influx and Net Accumulation of PIB , 2008, The open neuroimaging journal.

[13]  Ramon Casanova,et al.  Biological parametric mapping: A statistical toolbox for multimodality brain image analysis , 2007, NeuroImage.

[14]  M. Lubberink,et al.  Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  Paul Edison,et al.  A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  et al.,et al.  Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET , 2002, NeuroImage.

[17]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[18]  H. Arai,et al.  [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Birk Diedenhofen,et al.  cocor: A Comprehensive Solution for the Statistical Comparison of Correlations , 2015, PloS one.

[20]  Koen Van Laere,et al.  Validation of the cerebellum as a reference region for SPECT quantification in patients suffering from dementia of the Alzheimer type , 1999, Psychiatry Research: Neuroimaging.

[21]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[22]  N. Okamura,et al.  Preclinical Evaluation of [18F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer , 2016, Molecular Imaging and Biology.

[23]  B. Reisberg,et al.  Computed Tomography and Positron Emission Transaxial Tomography Evaluations of Normal Aging and Alzheimer's Disease , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[24]  J L Andersson,et al.  Brain regions associated with episodic retrieval in normal aging and Alzheimer’s disease , 1999, Neurology.

[25]  O. Ukoumunne,et al.  ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). , 2014, The Cochrane database of systematic reviews.

[26]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[27]  Young T. Hong,et al.  Early-Phase 11C-PiB PET in Amyloid Angiopathy-Related Symptomatic Cerebral Hemorrhage: Potential Diagnostic Value? , 2015, PloS one.

[28]  Egill Rostrup,et al.  Cerebral Blood Flow Response to Functional Activation , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[29]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[30]  E. P. Krenning,et al.  The diagnostic value of SPECT with Tc 99m HMPAO in Alzheimer's disease , 1994, Neurology.

[31]  Jiahe Tian,et al.  Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis , 2014, European Radiology.

[32]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[33]  S. Hirai,et al.  Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated byβ protein immunostain , 2004, Acta Neuropathologica.

[34]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[35]  Cindee M. Madison,et al.  Early 11C-PIB Frames and 18F-FDG PET Measures Are Comparable: A Study Validated in a Cohort of AD and FTLD Patients , 2011, The Journal of Nuclear Medicine.

[36]  B. Crain,et al.  Interlaboratory Comparison of Neuropathology Assessments in Alzheimer's Disease: A Study of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1994, Journal of neuropathology and experimental neurology.

[37]  Arne Brun,et al.  PATHOLOGICAL AND POSITRON EMISSION TOMOGRAPHIC CORRELATIONS IN ALZHEIMER'S DISEASE , 1985, The Lancet.

[38]  Anton Forsberg,et al.  The use of PIB-PET as a dual pathological and functional biomarker in AD. , 2012, Biochimica et biophysica acta.

[39]  H. Arai,et al.  Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease , 2013, The Journal of Nuclear Medicine.

[40]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[41]  Adriaan A Lammertsma,et al.  Cerebral blood flow and glucose metabolism in healthy volunteers measured using a high-resolution PET scanner , 2012, EJNMMI Research.